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Abstract: Stem cell therapy represents a promising approach in the treatment of several 
neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). The beneficial effect of 
stem cells is exerted by paracrine mediators, as exosomes, suggesting a possible potential use of 
these extracellular vesicles as non-cell based therapy. We demonstrated that exosomes isolated from 
adipose stem cells (ASC) display a neuroprotective role in an in vitro model of ALS. Moreover, the 
internalization of ASC-exosomes by the cells was shown and the molecules and the mechanisms by 
which exosomes could exert their beneficial effect were addressed. We performed for the first time 
a comprehensive proteomic analysis of exosomes derived from murine ASC. We identified a total 
of 189 proteins and the shotgun proteomics analysis revealed that the exosomal proteins are mainly 
involved in cell adhesion and negative regulation of the apoptotic process. We correlated the protein 
content to the anti-apoptotic effect of exosomes observing a downregulation of pro-apoptotic 
proteins Bax and cleaved caspase-3 and upregulation of anti-apoptotic protein Bcl-2 α, in an in vitro 
model of ALS after cell treatment with exosomes. Overall, this study shows the neuroprotective 
effect of ASC-exosomes after their internalization and their global protein profile, that could be 
useful to understand how exosomes act, demonstrating that they can be employed as therapy in 
neurodegenerative diseases. 
Keywords: extracellular vesicles; proteomic profiling; mesenchymal stem cells; amyotrophic lateral 
sclerosis; apoptosis; therapy 
 
1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the 
selective degeneration of upper and lower motoneurons. ALS is a multifactorial disease since several 
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pathogenetic mechanisms lead to motoneuron degeneration [1]. Due to this pathogenetic complexity, 
to date, no satisfactory treatment is available to cure or improve the quality of life of patients. The 
great interest of mesenchymal stem cells (MSC) as a therapeutic strategy in neurodegenerative 
diseases is due to their capability to migrate to damaged tissue and differentiate, contributing to 
stimulating the reparative processes [2,3]. Among the different sources of MSC, adipose stem cells 
(ASC) are easily available from liposuction, representing an interesting candidate in view to 
autologous transplantation [4]. Despite several preclinical and clinical applications provide evidence 
concerning the therapeutic potential of MSC in ALS, only a small number of transplanted cells reach 
the target tissue and differentiate [5,6]. To explain the therapeutic efficacy of MSC although the lack 
of cell engraftment, recent studies attribute the effect of stem cells to secretion of paracrine factors 
and to the release of extracellular vesicles [4,7]. This hypothesis provides the basis for a non-cell-
based therapy for the treatment of different neurodegenerative diseases, including ALS, that could 
avoid the unpredictable consequences of cell therapy. 
Exosomes are a group of extracellular vesicles 30 to 150 nm in diameter released by most cell 
types and can be taken up by recipient cells, covering an important role in intercellular 
communication [8]. Concerning the possible therapeutic use of exosomes isolated from MSC in 
neurodegenerative diseases, it has been shown that these vesicles stimulate nerve regeneration, 
remyelination, synaptic plasticity and neuronal protection [9–11]. Moreover, it has been reported that 
exosomes can protect dopaminergic neurons from neurodegeneration through the reduction of 
reactive oxygen species and apoptosis [12]. Farinazzo and colleagues demonstrated that, after 
oxidative stress, exosomes protect neuroblastoma cells and primary murine hippocampal neurons 
[13]. We here confirmed our previous data demonstrating the neuroprotective effect of exosomes 
isolated from ASC (ASC-exosomes) in an in vitro model of ALS [14]. In this previous study, we used 
the motoneuron-like cell line NSC-34 transfected with a vector expressing mutated human SOD1 
gene (the first gene identified to be related with ALS). The mutations studied were G93A, G37R and 
A4V, and we showed that, in all cases, exosomes protect the cells from oxidative stress. Since the 
content of exosomes (in terms of lipids, proteins, and RNAs) is related to the origin cell, vesicles 
obtained from a different source could exert a different effect. The importance of knowing the content 
of the exosomes could lead to a better understanding of their mechanism of action on recipient cells 
in view of a possible their therapeutic use. 
The objective of this study was to correlate the anti-apoptotic effect of ASC-exosomes after their 
internalization in the in vitro model of ALS with their comprehensive proteomic analysis. We used 
the NSC34 cells transfected with a vector expressing human SOD1(G93A) gene, since G93A mutation 
is the most commonly used to generate transgenic ALS models. We demonstrate that the biological 
effect on NSC-34(G93A) cells was determined by the uptake of ASC-exosomes. To this purpose, we 
used a method to label exosomes with ultra-small superparamagnetic iron oxide nanoparticles 
(USPIO, 4–6 nm), that allow the detection of labelled exosomes (exosomes-USPIO) in the cells [15]. 
Moreover, the shotgun proteomics analysis performed to assess the content of the vesicles revealed 
that the exosomal proteins are mainly involved in cell adhesion and negative regulation of the 
apoptotic process. In relation to this, we observed an upregulation of anti-apoptotic protein Bcl-2  
and downregulation of pro-apoptotic proteins Bax and cleaved caspase-3 after treating cells with 
exosomes, correlating the protein content to the neuroprotective effect on NSC-34 cells. These 
findings shed light on how these exosomes mediate their beneficial effects and provide for the first 
time a rationale for their use in treating neurodegenerative diseases. 
2. Material and Methods 
2.1. ASC and NSC-34 Cell Cultures 
The ASC were isolated from inguinal adipose tissues of 8/12 week-old C57BL/6J mice (Charles 
River, Italy), as previously described [16]. The experiments were performed with the approval of the 
Italian Minister of Health, following the NIH guide for the use and the care of laboratory animals, in 
accordance with the current European Communities Council Directive (2010/63/EEC) and conformity 
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to the international guidelines, minimizing the number of animals used and avoiding their 
sufferance. The mice were maintained under controlled environmental parameters with food and 
water ad libitum, with 12 h of light and dark cycle. Briefly, the tissue was incubated in Hank’s 
Balanced Salt Solution (HBSS, Life Technologies, Milan, Italy) with collagenase type I (Life 
Technologies) and bovine serum albumin (BSA, AppliChem, Euroclone, Milan, Italy). The stromal 
vascular fraction (SVF) obtained after centrifugation was resuspended in NH4Cl, centrifuged and 
filtered through a 40-μm nylon mesh to remove cell debris. ASC were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) with 10% heat-inactivated Fetal Bovine Serum (FBS), 100 U/mL 
penicillin and 100 μg/mL streptomycin (all from GIBCOLife Technologies, Milan, Italy) and 
incubated at 37 °C in a 5% CO2 atmosphere. Murine ASC were recognized by immunophenotype 
using monoclonal antibodies, as previously described [16]. These cells were used to isolate exosomes. 
The NSC-34 motoneuron-like cell line was purchased from CELLutions Biosystems Inc (Ontario, 
Canada). NSC-34 cells were transfected with the human SOD1 gene (hSOD1) carrying G93A point 
mutation (NSC-34(G93A)), as previously described [14]. NSC-34 cells were cultured in DMEM with 
10% heat-inactivated FBS, 100 U/mL penicillin and 100 μg/mL streptomycin and incubated at 37 °C 
in a 5% CO2 atmosphere. These cells were used to confirm the neuroprotective effect of exosomes, to 
validate effect of exosomal proteins involved in the apoptotic pathway and to determine the 
internalization of exosomes. 
2.2. Expression Vectors and Generation of Tetracycline-Inducible Cells Overexpressing His-HA-
SOD1(G93A) 
The plasmid pcDNA3-SOD1(G93A), expressing the hSOD1 gene containing the G93A mutation, 
was purchased from Addgene (Cambridge, MA, USA) and used as template to amplify by PCR the 
respective cDNA. Briefly, hSOD1(G93A) cDNA was amplified with PfuDNA polymerase (Stratagene) 
using the following primers containing Sgf I and Mlu I restriction sites: Fw 
5′GAGGCGATCGCCGCGACGAAGGCCGTGTGCGTGCTG3′ (Sgf I); Rv 5′ 
GCGACGCGTTTATTGGGCGATCCCAATTACAC3′ (MluI). The amplified fragment was digested 
with Sgf I and MluI enzymes and cloned into the pCMV6-AN-His-HA plasmid (PS100017, OriGene, 
Rockville, MD) to give the vector pCMV6-HIS-HA-SOD1(G93A), expressing the mutant hSOD1 gene 
in fusion with an amino-terminal polyhistidine (His) tag and a hemagglutinin (HA) epitope. 
To generate the lentiviral vectors for the conditional expression of SOD1 mutants, the 
hSOD1(G93A) gene was excised from pCMV6-HIS-HA-SOD1(G93A) plasmid by using BamHI and 
XhoI enzymes and subcloned in the same sites of the vector pENTR1A (w48-1, Addgene). This vector 
was then recombined into pLenti CMV/TO Puro DEST (670-1, Addgene) using LR-Clonase (Life 
Technologies) to give a lentiviral vector expressing hSOD1(G93A) gene under the control of a 
doxycycline-inducible promoter [14]. 
To establish an inducible cell line overexpressing the hSOD1(G93A) mutant, NSC34 cells were 
first transduced with the pLentiCMV_TetR_Blast vector (716-1, Addgene), that constitutively 
expresses high levels of the tetracycline (Tet) repressor under the control of a CMV promoter, and 
selected for 7 days using 10 µg/mL Blasticidin (Sigma). After drug selection, the stable cells were 
infected with the lentiviral vectors expressing hSOD1(G93A) in the presence of 4 µg/mL polybrene. 
The selection of transduced cells was then conducted using 5 µg/mL puromycin. The expression of 
hSOD1 mutants was induced by adding 2 µg/mL doxycycline (Clontech) to the culture medium for 
the last 48 h of culture. The efficiency of SOD1 mutant induction was quantified with a high content 
imaging approach, as previously described [14]. 
2.3. ASC-Exosomes and Exosomes-USPIO Isolation 
Exosomes were isolated from the culture medium of 1 × 107 ASC. Murine ASC were cultured to 
confluence. To isolate exosomes from ASC cell culture conditioned medium and to avoid any 
contamination of shed membrane fragments and vesicles from serum, FBS deprivation for 48h was 
made. Cell culture supernatants were then collected and PureExo®  Exosome isolation kit (101Bio, 
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Mountain View, CA, USA) was used for exosomes isolation, following the manufacturer’s protocol. 
The determination of the protein content of exosomes was determined by Bicinchoninic Protein 
Assay (BCA) method, using the manufacturer’s protocol (Thermo Scientific™ Pierce™ BCA™ 
Protein Assay). Moreover, the concentration of ASC-exosomes was assessed by NanoSight 
instrument (Izon Nanoparticle Tracking Analysis). The ASC-exosomes were used for their 
characterization by transmission electron microscopy (TEM) and western blot, for the proteomic 
analysis and for the evaluation of the neuroprotective effect in NSC-34 cells. 
To obtain labelled ASC-exosomes, ASC (107 cells) were incubated with 200 µg Fe/mL of ultra-
small superparamagnetic iron oxide nanoparticles (USPIO, 5–7 nm) for 24 h, washed and deprived 
of FBS for 48 h to avoid any contamination of vesicles from serum. After deprivation, ASC 
supernatants were collected and exosomes-USPIO were isolated using PureExo®  Exosome isolation 
kit (101Bio, Mountain View, CA, USA). The determination of the protein content of exosomes was 
determined by the BCA method (Thermo Scientific™ Pierce™ BCA™ Protein Assay). The exosomes-
USPIO can be detected by TEM, as previously reported [15]. The exosomes-USPIO were used to 
detect their internalization by the NSC-34(G93A) cells by TEM. 
2.4. Electron Microscopy of ASC-Exosomes 
Exosomes pellet was fixed in 2% glutaraldehyde in Sorensen buffer (pH 7.4) for 2 h, post-fixed 
in 1% osmium tetroxide (OsO4) in aqueous solution for 2 h, dehydrated in graded concentrations of 
acetone and embedded in Epon–Araldite mixture (Electron Microscopy Sciences, Fort Washington, 
PA, USA). The semithin sections (1 µm in thickness) were examined by light microscopy (Olympus 
BX51, Olympus Optical, Hamburg, Germany) and stained with toluidine blue. The ultrathin sections 
were cut at a 70 nm thickness, placed on Cu/Rh grids with Ultracut E (Reichert, Wien, Austria), and 
observed with TEM using a Morgagni 268D electron microscope (Philips). 
2.5. Biochemical Characterization of ASC-Exosomes by Western Blot 
Analysis of exosomes by immunoblotting was performed using standard protocols: Proteins 
were denatured, separated on 4–12% polyacrylamide gels, transferred onto a nitrocellulose 
membrane and probed with antibodies against heat shock protein 70 (HSP70, 1:100 Santa Cruz 
Biotechnology, sc-1060), and tetraspanins CD9 (1:100 MM2/57, Millipore CBL-162) and CD81 (1:100 
Santa Cruz Biotechnology, sc-9158) followed by appropriate horseradish peroxidase (HRP) 
conjugated secondary antibodies against the primary antibody (all secondary antibodies were from 
Dako Agilent). ASC lysates were used as the positive control. The blots were then incubated with a 
chemiluminescent HRP substrate and detected with G:BOX F3 GeneSys (Syngene, UK). 
2.6. Sample Preparation for Shotgun Proteomics 
ASC-exosomes were collected and lysed in 1X PBS added with protease inhibitors cocktail 1X 
(Roche) and 1% sodium dodecyl sulphate (SDS) (Bio-Rad). Protein extraction was performed by 5–6 
cycles of sonication; then a four-fold volume of ice-cold acetone was added to samples and protein 
precipitation was conducted overnight at −20 °C. Samples were then centrifuged at 14,000× g for 10 
min at 4 °C, and the pellet was resuspended in 100 mM NH4HCO3. Protein concentration was 
measured with BCA Protein Assay (Thermo Fisher Scientific) using bovine serum albumin as a 
standard. Before the shotgun proteomic analysis, proteins were digested as already described [17]. 
Briefly, 40 µg of proteins were reduced by using dithiothreitol and alkylated with iodoacetamide. 
Then, after dilution with 100 mM NH4HCO3 solution, 5 µg of trypsin (Promega, Sequence Grade) 
was added and digestion was performed overnight at 37 °C. Trypsin activity was stopped by adding 
2 µl of neat formic acid and digests were dried by Speed Vacuum. 
2.7. Mass Spectrometry Analysis 
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The digested samples were analyzed on a micro-LC (Eksigent Technologies, Dublin, CA, USA) 
interfaced to a 5600+ TripleTOF mass spectrometer system (AB Sciex, Concord, Canada) equipped 
with a DuoSpray Ion Source and a CDS (calibrant delivery system). The LC column was a Halo Fused 
C18 with a pre-column ProteCol C18G. The mobile phase was a mixture of 0.1% (v/v) formic acid in 
water (A) and 0.1% (v/v) formic acid in acetonitrile (B), eluting at a flow-rate of 15 μL min−1 at an 
increasing concentration of solvent B from 2% to 86% in 17 min. The injection volume was 4 μL and 
the oven temperature was set at 40 °C. For identification purposes, the mass spectrometer analysis 
was performed using a mass range of 100–1500 Da (TOF scan with an accumulation time of 0.25 s), 
followed by a MS/MS product ion scan from 200 to 1250 Da (accumulation time of 5 ms) with the 
abundance threshold set at 30 cps (35 candidate ions can be monitored during every cycle). The ion 
source parameters in the electrospray positive mode were set as follows: Curtain gas (N2) at 25 psig, 
nebulizer gas GAS1 at 25 psig, and GAS2 at 20 psig, ion spray floating voltage (ISFV) at 5000 V, source 
temperature at 450 °C and declustering potential at 25 V. 
The DDA (Data Dependent Analysis) files were searched using Protein Pilot software v. 4.2 (AB 
SCIEX, Concord, Canada) and Mascot v. 2.4 (Matrix Science Inc., Boston, MA, USA). Trypsin as a 
digestion enzyme was specified for both software. For Mascot, we used two missed cleavages, the 
instrument was set to ESI-QUAD-TOF and the following modifications were specified for the search: 
Carbamidomethyl cysteine as a fixed modification and oxidized methionine as variable modification. 
A search tolerance of 0.08 Da was specified for the peptide mass tolerance, and 10 ppm for the MS/MS 
tolerance. The charges of the peptides to search for were set to 2+, 3+ and 4+, and the search was set 
on monoisotopic mass. The UniProt Swiss-Prot reviewed database containing mouse proteins 
(version 2015.20.07, containing 23,304 sequence entries, UniProt Consortium) was used and a target-
decoy database search was performed. The false discovery rate (FDR) was fixed at 1% [18,19]. 
2.8. Bioinformatics Analysis 
The identified exosomal proteins were subjected to bioinformatics analyses in order to: 
Investigate the presence of surface proteins, classify them on the basis of gene ontology, identify the 
molecular pathways in which they are involved, and highlight any protein–protein interaction 
networks. In particular, the detection of identified exosomal proteins located on the plasma 
membrane (which potentially can be shed and released to the extracellular space) was performed by 
TransMembrane prediction using hidden Markov models (TMHMM 2.0 server) 
(http://www.cbs.dtu.dk/services/TMHMM/) which predicts transmembrane helices [20]. Functional 
annotation of identified proteins was employed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) (v6.8) (http://david.abcc.ncifcrf.gov/) [21] to identify gene ontology 
(GO) biological processes (GOBPs), molecular function (GOMFs) and cellular component (GOCCs). 
The GOBPs, GOMFs, and GOCCs enriched by the list of proteins were identified as the ones with p-
value < 0.01 calculated by DAVID. 
The Cytoscape (v3.5.0) ClueGO (v.2.5.0) plugin [22] was used to visualized enriched pathways 
associated with the Kyoto Encyclopaedia of Genes and Genome (KEGG) database. In brief, KEGG 
pathways were explored with medium specificity and a kappa score of 0.4. An enrichment/depletion 
method with a two-sided hypergeometric test was applied, correct with the Bonferroni step down for 
each p-value calculation. Enriched pathways with a p-value < 0.05 were considered significant. 
Finally, in order to predict protein-protein interaction, the identified proteins of ASC-exosomes 
were analyzed using STRING software (http://string-db.org) [23]. STRING analysis was performed 
by setting the species under investigation (Mus musculus) with a medium confidence level (score 0.4); 
we retrieved interactions based on experimental and database knowledge, excluding all other 
prediction methods implemented in STRING (such as co-expression and text-mining). Additional 
white nodes and network depth were kept to the minimum value (1), to exclude as many false 
positive interactions as possible. 
2.9. Immunoblotting of Akt and SOD1 
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Exosomes and ASC were subjected to immunoblotting analysis using the following protocol: 
Proteins were extracted in RIPA buffer (Sigma-Aldrich) containing protease inhibitor cocktail tablets 
1X (Roche), sonicated 10 min and then lysates were clarified by centrifugation at 8000× g for 10 min 
at 4 °C. Supernatants were harvested and protein content was determined by BCA assay (Sigma-
Aldrich). Samples were denatured, separated on 10–20% polyacrylamide gels, transferred onto a 
PVDF (polyvinylidene difluoride) membrane and probed with antibodies against phospho-Akt 
(Ser473) (1:1000, Cell Signalling Technologies; #9271), and SOD1 (1:1000, NBP1-31204), followed by 
an appropriate HRP-conjugated secondary antibody against the primary antibody (Santa Cruz 
Biotechnology, sc-2005). ASC lysate was used as a positive control. The blots were then incubated 
with a chemiluminescent HRP substrate and detected with ChemiDoc MP imaging system (Bio-Rad). 
2.10. SOD1 Zymogram Assay 
ASC-exosomes and adipose serum-deprived stem cells were lysed in 1XPBS containing protease 
inhibitor cocktail tablets 1X (Roche) for four times at 25 Hz for 10 s. Samples (60 μg per lane) were 
loaded in a native buffer and separated on a 15% (v/v) non-denaturing polyacrylamide gel for 3 h at 
40 mA at 4 °C. The gel was stained for 45 min in 50 mM potassium phosphate (KH2PO4) pH 7.4 
containing 275 μg/mL nitro blue tetrazolium (NBT) (ThermoFisher), 65 μg/mL riboflavin (Sigma-
Aldrich) and 3.2 μL/mL tetra methyl ethylene diamine (TEMED) (Sigma-Aldrich) at room 
temperature in the dark. Gel was then illuminated for 15 min until sufficient contrast between 
achromatic zones (dismutase activity) and blue background was achieved and then scanned for 
documentation. ASC cells extract was used as positive control. An identical gel was stained with 
Coomassie brilliant blue to verify the equal amount of protein extract loaded among the different 
samples. 
2.11. NSC-34 Cell Treatment and Viability 
The NSC-34(G93A) cells were seeded at a density of 2 × 104 and exposed to H2O2 (100 µM) for 6 
h with or without the presence of ASC-exosomes (0.2 µg/mL, corresponding to 6–8 × 105 particles/mL) 
in the culture medium. The number of cells seeded, the quantity of exosomes able to protect the cells, 
the concentration of H2O2 used as pathological insult to induce apoptosis, and the time of H2O2 
incubation with or without exosomes were identified in our previously study [14]. Cells (2 × 104) 
without treatments were used as a basal condition. Cell viability and apoptotic cells were evaluated 
by cell counting after acridine orange/propidium iodide (AO/PI, both from Sigma-Aldrich) double 
staining. A total of 10 μL of AO/PI was added and spread by placing a coverslip over it. The apoptotic 
and live cells were visualized using an upright fluorescent microscope (DM6000B, Leica 
Microsystem) by their red or green fluorescence and their nuclear morphology. Each experiment was 
performed at least three times, and for each condition three replicates were performed. The number 
of stained cells were counted in 20 random field using the 20× objective. To evaluate the 
neuroprotective effect of ASC-exosomes on NSC-34(G93A) cells, the univariate analysis of variance 
(ANOVA) and Bonferroni post-hoc tests were performed to evaluate differences between the 
experimental conditions. Significance was accepted at p < 0.05. 
2.12. Evaluation of Apoptotic Markers by Western Blot 
The NSC-34(G93A) cells were exposed to H2O2 for 6h with or without the presence of ASC-
exosomes in the culture medium, as previously described [14]. A total of 2 × 104 NSC-34(G93A) cells 
were used to perform western blot analysis. The western blot was performed by using pooled 
biological samples. Immunoblot was performed as previously described [24]. Briefly, after separation 
on 10–20% SDS-PAGE, proteins were electroblotted on a PVDF membrane and subjected to 
immunorevelation. Cleaved caspase 3 was detected by using anti-(cleaved) caspase 3 (1:300, Cell 
Signalling Technologies; #9661) and anti-rabbit secondary antibody-HRP conjugate (Santa Cruz 
Biotechnology, sc-2004); Bcl-2  was investigated by using anti-Bcl-2  (1:200, Biosource) primary 
antibodies and anti-rabbit secondary antibody-HRP conjugate (Santa Cruz Biotechnology, sc-2005) 
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and Bax was detected by using anti-Bax (N20) (1:200; Santa Cruz Biotechnology sc-493) primary 
antibodies and anti-rabbit secondary antibody-HRP conjugate (Santa Cruz Biotechnology, sc-2005). 
The immunocomplexes were visualized by chemiluminescence using the ChemiDoc MP imaging 
system (Bio-Rad) and the intensity of the chemiluminescence response was measured by processing 
the image with Image Lab software (Bio-Rad). 
2.13. Internalization of Exosomes-USPIO by NSC-34(G93A) Cells 
To detect the internalization of ASC-exosomes by the cells, exosomes labelled with USPIO 
nanoparticles, that allowed the visualization by TEM, were used. The NSC-34(G93A) cells were 
seeded at a density of 2 × 104 with the presence of exosomes-USPIO (0.2 µg/mL, corresponding to 6–
8 × 105 particles/mL) in the culture medium for 6 h. After the incubation time, the cells were washed 
with PBS, trypsinized and centrifuged. For ultrastructural morphology of cells, the pellet was fixed 
in 2% glutaraldehyde in Sorensen buffer (pH 7.4) for 2 h. The samples were post-fixed in 1% osmium 
tetroxide (OsO4) for 2 h, cut, dehydrated in graded concentrations of acetone and embedded in Epon-
Araldite mixture (Electron Microscopy sciences, Fort Washington, PA, USA). The semithin sections 
(1 µm in thickness) were examined by light microscopy (Olympus BX51, Olympus Optical, Hamburg, 
Germany) and stained with toluidine blue. The ultrathin sections were cut at a 70 nm thickness, 
placed on Cu/Rh grids with Ultracut E (Reichert, Wien, Austria). TEM images were acquired with a 
Philips Morgagni TEM operating at 80kV and equipped with a Megaview II camera for digital image 
acquisition. 
3. Results 
3.1. Isolation and Characterization of ASC-Exosomes 
Exosomes were obtained with an exosomes isolation kit and their protein concentration was 
quantified. The yield for each isolation was about 100–150 µg of protein. The concentration of 
nanovesicles obtained by NanoSight were 6–8 × 108 particles/mL. Ultrastructure analysis of the 
exosomes by TEM revealed round vesicles with lipid bilayers with a diameter of 50 to 150 nm (Figure 
1A). Western blot analysis revealed specific exosomal markers including HSP70 (70 kDa), CD9 (25 
kDa) and CD81 (26 kDa) (Figure 1B). These results confirm that size, morphology and the presence 
of specific protein markers are consistent with a previous report [25]. 
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Figure 1. TEM and western blot analysis of adipose stem cells (ASC)-exosomes. Electron microscopy 
shows vesicles with characteristic morphology and size of exosomes. Scale bar, 100 nm (A). The blots 
show western blot detection of the expression of HSP70 (70 kDa), CD9 (25 kDa) and CD81 (26 kDa) 
in exosomes (EXO); ASC lysates (ASC) was used as positive control (B). 
3.2. Proteomic Analysis of ASC-Exosomes and Annotations of Identified Proteins 
The shotgun proteomic analysis of exosomes was performed to obtain the complete 
characterization of the proteome. We identified a total of 189 proteins with a peptide confidence cut-
off of 99% (FDR < 1%). The identities of these proteins are presented in Supplementary material Table 
S1. 
After MS the identified exosomal proteins were analyzed using bioinformatics analysis. For each 
identified ASC-exosomes protein, the number of transmembrane regions was predicted using 
TMHMM. In particular, a total of 16 proteins were predicted to have transmembrane domains 
(TMDs), of which one has ten TMDs, i.e., ATPase class II type 9B, and all the others with one TMD; 
the remaining proteins were localized as outside (169) or inside the membrane [22] (Supplementary 
material Table S2). 
Functional annotation of ASC-exosomes proteome was examined using DAVID software by 
performing enrichment analysis of GOBPs, GOMFs, and GOCCs (Figure 2, and Supplementary 
material Table S3). The 189 identified proteins have been associated with a total of 31 statistically 
significant (p-value < 0.01) GO terms for biological process. Interestingly, the most important 
significantly enriched GOBPs categories included cell adhesion (9.5%), negative regulation of 
apoptotic process (6.9%) and angiogenesis (6.3%) (Figure 2A). The most enriched GO terms for 
molecular functions were protein binding (40.7%), metal ion binding (24.9%), and poly(A) RNA 
binding (21.7%) (Figure 2B). Moreover, the enrichment analysis of GOCCs revealed that exosomal 
proteins were localized mainly into the extracellular exosome (i.e., vesicles released into the 
extracellular region) (52.9%), as well as the cytoplasm (47.6%) and extracellular region (41.8%) (Figure 
2C). 
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Figure 2. Gene ontology (GO) enrichment of the ASC-exosomes identified proteins according to 
Database for Annotation, Visualization and Integrated Discovery (DAVID) functional annotation. The 
top 10 enriched biological process (A) molecular function (B) and cellular component (C) are reported. 
The percentage represents the portion of the genes encoding the proteins with the corresponding gene 
ontology biological processes (GOBPs), gene ontology molecular functions (GOMFs) or gene ontology 
cellular components (GOCCs) in the ASC-exosomes proteins. 
To further explore the enriched pathways associated with ASC-exosomes proteins, we have 
imported the list of identified proteins in the ClueGO app for Cytoscape platform to create a network 
of the overrepresented GO terms. Only significant pathways or terms were presented by setting the 
statistical threshold (p-value < 0.05) and using the KEGG database as a reference (Supplementary 
material Table S4). Multiple functions related to focal adhesion (such as Extracellular matrix receptor 
interaction, PI3K-Akt signaling pathway, protein digestion and adsorption), as well as to apoptosis, 
antigen processing and presentation, platelet activation, and proteoglycan in cancer were enriched 
for ASC-exosomes proteins (Figure 3). 
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Figure 3. Cytoscape based ClueGo/CluePedia pathway analysis and visualization. Enriched 
pathways were obtained from the Kyoto Encyclopaedia of Genes and Genome (KEGG) database. 
Terms are grouped based on shared genes (kappa score) showed in different colors. The size of nodes 
indicated the degree of significance. The most significant term defined the name of the group. 
Finally, to investigate the interaction pattern of annotated proteins and to elucidate the physical 
interaction between them, we created a protein–protein interaction network of the ASC-exosomes 
proteome using STRING software. STRING analysis emphasized that ASC-exosomes proteins 
interact within the actin-myosin and collagen complexes, and showed functional relationship (i.e., 
contribute jointly to a specific biological function) regarding the mechanism of response to stress, 
PI3K-Akt signaling and interactions at extracellular matrix level (Figure 4). Concerning these 
pathways, several molecules could have a role to counteract neurodegenerative mechanisms. 
Through the proteomic analysis, we found some interesting proteins to counteract pathogenic 
mechanisms, as SOD1, that can destroy free superoxide radicals, the neuroprotective ribonuclease 
RNase 4, the insulin-like growth factors Igf1 and Akt, that play a role in inhibiting apoptosis 
(Supplementary material Table S1, Figure 4). Since only the active form of proteins allows the correct 
function of the molecules, the validation of the enzymatically active form of the interested molecules 
was required. Among the interest proteins, RNase4 and Igf1 are already enzymatically active, while 
SOD1 and Akt required some post-traductional modification to be activated. To this purpose, the 
presence of the active form in ASC-exosomes was validated. 
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Figure 4. Protein network of identified ASC-exosomes proteins. Schematic view of known and 
predicted protein interactions according to the STRING database (v. 10). Each node represents a 
protein, and each edge represents an interaction. Only interactions with the medium confidence score 
(0.4) are shown. Interactions include physical and functional associations, showing the evidence view. 
3.3. Expression Profile of Phospho-Akt and SOD1 Proteins in ASC-Exosomes 
It is known that, in ALS, the major mechanisms involved in motoneurons death are linked to 
oxidative stress and apoptosis. Since the proteomic analysis revealed the presence of proteins 
involved in these pathways, we focus attention on validating the presence of the active form of 
selected proteins (phospho-Akt for PI3K-Akt signaling pathway and SOD1 for response to oxidative 
stress mechanism). 
To investigate if an Akt protein is enzymatically active in ASC-exosomes, the immunoblot 
analysis of phospho-Akt (Ser473) was performed. As shows in Figure 5A, Akt was found active both 
in ASC and exosomes, thus confirming the presence of active proteins in ASC-exosomes. Notably, 
the multiple bands detected of phospho-Akt may represent the phosphorylated forms of the different 
Akt isoforms (i.e., Akt1, Akt2, and Akt3) which are all detected by the antibody. 
Moreover, the presence of SOD1 protein, previously detected by proteomic profiling of ASC-
exosomes, was validated by western blot (Figure 5B). In addition, SOD1 is observed as multiple bands 
in exosomes, these may represent spliced variants, truncated protein or post-translational 
modifications, which may be detected by the antibody used. 
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Figure 5. Western blot analysis of phospho-Akt and SOD1 expression in ASC-exosomes and ASC. The 
blots show western blot detection of the expression of phospho-Akt (60 kDa) (A) and SOD1 (16 kDa) 
(B) in exosomes (EXO); ASC lysates were used as positive control. Amido Black staining was used as 
total loading control (C). 
In order to assess if the SOD1 proteins contained in ASC-exosomes are enzymatically functional, 
we performed a zymogram assay. The native gel was stained using a solution of nitro blue 
tetrazolium and riboflavin. Riboflavin is a source of superoxide anions which interact with nitro blue 
tetrazolium and reduce the yellow tetrazolium within the gel to a blue precipitate. Since SOD inhibits 
this reaction, a colorless band indicates SOD activity [26]. 
As showed in Figure 6, SOD1 was found active both in ASC and exosomes, thus confirming the 
presence of active SOD1 in ASC-derived exosomes. 
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Figure 6. Zymogram assay of SOD1 protein. The assay shows that exosomes (EXO) contain the active 
form of SOD1 protein. The ASC and deprived ASC (ASC-) were used as the positive control (A). 
Comassie blue staining was used as total loading control (B). 
3.4. NSC-34(G93A) Cells Viability after ASC-Exosomes Treatment 
The beneficial effect of ASC-exosomes was evaluated on NSC-34(G93A) cells, confirming our 
previous data [14]. Cells were exposed to H2O2 to induce apoptosis [27] with or without the presence 
of ASC-exosomes. The exosomes neuroprotective effect was evaluated in terms of cell morphology, 
cell viability and apoptosis by cell counting after AO/PI double staining. The administration of ASC-
exosomes in the culture medium determined a protective effect with an increase in cell viability, as 
detected after AO/PI double staining, where live cells showed green fluorescence and apoptotic cells 
showed orange/red fluorescence (Figure 7A). The H2O2 treatment determined a high cell death 
compared to the basal condition (with a mean of 13.94% of cell viability; p < 0.001), while the treatment 
with ASC-exosomes rescued the cells from apoptosis, with a significant increase in cell viability 
compared to the cells treated with H2O2 (mean of 64.98% of cell viability; p < 0.001) and restored cell 
viability with no significant difference compared to the control (basal condition, mean of 78.82% of 
cell viability) (Figure 7B). 
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Figure 7. Acridine orange/propidium iodide (AO/PI) double staining on NSC-34(G93A) cells. 
Apoptotic and live cells were visualized after AO/PI double staining. The green fluorescence staining 
by AO indicate live cells, while orange/red fluorescence indicate the PI staining that bound to DNA 
after damaged membranes. The image shows cells in a basal condition (no cell death was detected 
and nucleus is uniformly distributed), cells after H2O2 treatment (the nucleus is located in bias and 
apoptosis-associated changes of cell membranes can be detected, indicating a process of 
disintegration) and cells after treatment with H2O2 and exosomes (H2O2 + EXO) in which a rescue of 
cells from death is detected, with an increase in cell viability compared to cells after H2O2 treatment 
Magnification 20× (A). The graph shows the percentage of cell viability of NSC-34(G93A) cells in basal 
condition and after H2O2 and ASC-exosomes treatment (H2O2 + EXO). Cell viability significant 
increased after ASC-exosomes treatment. One-way ANOVA and Bonferroni post-hoc analysis were 
performed between all the experimental conditions (***p < 0.001) (B). 
3.5. Internalization of Exosomes-USPIO by NSC-34(G93A) Cells 
To demonstrate that the effect on cell viability and the modulation of apoptotic pathway were 
induced by a biological activities of ASC-exosomes, the internalization of the vesicles by the cells was 
detected. To this purpose, the cells were incubated with exosomes-USPIO for 6 h, the time in which 
the neuroprotective effect was observed. Images of cells without exosomes incubation were used as 
the negative control (data not shown). 
The cells visualized by TEM showed a morphology without alterations or damage after ASC-
exosomes treatment (Figure 8A). Cells were characterized by a heterochromatic nucleus, cytoplasm 
with polyribosome, a high number of mitochondria and an expanded endoplasmic reticulum. In the 
cytoplasm were present phospholipidic membrane structures contained high electron-density 
particles, whose dimensions could be attributable to USPIO nanoparticles used to label ASC-
exosomes (Figure 8B,C). The presence of these nanoparticles inside the cells suggested the 
intracellular internalization of exosomes content by the cells. Moreover, high electron-density 
particles were not found in the cytosol, in the nucleus or associated to the cell membrane. 
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Figure 8. TEM images of cells treated with exosomes-ultra-small superparamagnetic iron oxide 
nanoparticles (USPIO). TEM images showed no damaged cell after ASC-exosomes treatment; 
magnification 4400×, scale bar 1 µm (A). In (B) note a representative image of phospholipidic 
membrane structure contained high electron-density particles, whose dimension are attributable to 
USPIO nanoparticles used to label ASC-exosomes; magnification 46,000×, scale bar 100 nm. In (C), a 
higher magnification of the section squared in (B) is shown; magnification 140,000×, scale bar 50 nm. 
3.6. Expression Profile of Apoptotic Markers in Exosome-Treated NSC-34(G93A) Cells 
To investigate the neuroprotective potential of ASC-exosomes which was suggested by the 
identified proteins, the immunoblot analysis of some apoptotic markers was performed. In particular, 
we compared the expression level of the pro-apoptotic proteins cleaved-caspase 3 and Bax and of the 
anti-apoptotic protein Bcl-2  in NSC-34(G93A) cells after 6h of exposure to H2O2 in the presence or 
absence of ASC-exosomes. As shown in Figure 9A, the expression level of Cleaved caspase 3 (~17/19 
kDa) was increased after H2O2 cell treatment, compared to untreated cells. The two molecular weights 
indicate the fragments detected by the antibody (Cell Signaling: 9661), i.e., the large fragments (17/19 
kDa) of activated caspase-3 resulting from cleavage adjacent to Asp175. Indeed, Caspase-3 activation 
occurs in two stages: First, caspase-3 pro-forms are cleaved by upstream caspases (such as active 
caspase-8) at Asp175 to generate intermediate heterotetramer complexes consisting of two p19 and 
two p12 peptides (p19/p12 complexes); then, the second stage involves removal of the short pro-
domain from the p19 peptides by autocatalytic processing, and cleavage at residue Asp28, to generate 
the fully mature p17/p12 form of the enzyme [28]. 
On the other hand, the activated form of caspase-3 was reduced in cells treated with ASC-
exosomes, compared to the cells treated with H2O2 and appeared similar to one of the untreated cells. 
In addition, we found Bax (~21 kDa) reduction in cells treated with exosome compared to H2O2 
treated cells (Figure 9B). These data point out a protective role of exosomes in counteracting the 
expression of pro-apoptotic proteins. Concerning the anti-apoptotic protein Bcl-2  (~26 kDa), the 
immunoblot results showed that it was increased in cells exposed to H2O2 in the presence of ASC-
exosomes compared to cells without exosomes (Figure 9C). 
Altogether these results underline the neuroprotective role of exosomes in counteracting a stress 
stimulus, giving an explanation of our previous published data in which we found an increase of cell 
survival after exosomes treatment compared to cells exposed to only H2O2 [14]. 
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Figure 9. Expression profile of apoptotic markers in NSC-34(G93A) cells. The blots show western blot 
analysis of Cleaved Caspase 3 (A), Bax (B) and Bcl-2  (C) proteins performed in NSC-34(G93A) cells 
(used as control, CNTR), NSC-34 (G93A) cells treated with H2O2 and NSC-34 (G93A) cells treated with 
H2O2 and exosomes (EXO). Amido Black staining was used as total loading control (D). 
4. Discussion 
The great interest of the scientific community in relation to the possible use of exosomes in a 
pathological condition is due to their role in intercellular communication [8]. Moreover, in the 
therapeutic application of stem cells, there is evidence that these cells exert their beneficial effect 
through the release of exosomes instead of their engraftment [7]. These extracellular vesicles, after 
their release, can be taken up from the other living cells, where they modify cell behavior. In recent 
years, several studies highlight the potential therapeutic use of exosomes in different diseases 
[4,29,30]. The effect of exosomes is strictly correlated to their content, that depends on the origin cells 
[29]. In view of a therapeutic application of exosomes, it is crucial to know the content of these vesicles 
to understand their mechanism of action. Moreover, this knowledge could open the way to 
manipulate the origin cells to obtain exosomes that are rich in the molecule directly implicated in the 
neuroprotective action. 
Cells 2019, 8, 1087 17 of 22 
 
Several studies report the proteomic content of extracellular vesicles isolated from different 
sources such as bone marrow MSC, umbilical cord, placenta, human ASC and human milk [31–34]. 
In our study we describe, for the first time, a comprehensive proteomic analysis of exosomes isolated 
from murine adipose stem cells. The ASC-exosomes proteomic profiling was performed to elucidate 
their neuroprotective mechanism of action pointed out in our previous data in an in vitro model of 
ALS [14] and this was confirmed in this study. We demonstrated that the presence of ASC-exosomes 
protects NSC-34 cells, transfected with different mutations of the human SOD1 gene, from oxidative 
damage, increasing cell viability [14]. 
The proteomic analysis of ASC-exosomes revealed the presence of 189 exosomal proteins, that 
are mainly implicated in cellular pathways crucial to the protective effect of the vesicles, e.g., cell 
adhesion and negative regulation of the apoptotic process. As shown by the protein network and 
pathway analysis, this reveals the identity of the proteins and their interaction in a specific cellular 
pathway; the major proteins are implicated in response to stress and in the PI3K-Akt signaling 
pathway. 
In ALS, oxidative stress and alteration of axonal transport are typical features of the disease 
pathogenesis [4]. In relation to this, the presence of proteins involved in the response to stress in ASC-
exosomes, such as SOD1 and SOD3 are able to destroy free superoxide radicals and cytoskeleton 
proteins involved in cytoplasmic transport, and this could explain their protective effect on in vitro 
model of ALS. Moreover, the presence of SOD1 could replace the enzymatic function of mutated 
SOD1, improving the response of ALS motoneurons to oxidative stress. 
Besides, the presence of the ribonuclease RNase 4 in ASC-exosomes could be potential 
contributors to exosomes neuroprotection. The RNase 4 protein, displaying an angiogenic action, 
seems to be critical for ALS. In fact, the angiogenic, neurogenic and neuroprotective activities of 
RNase 4 have been recently demonstrated [35]. In addition, mutations in the RNase 4 gene were 
reported in ALS patients [36], confirming a potential use of ASC-exosomes as therapy in ALS. 
Concerning the proteins involved in the PI3K-Akt signaling pathway, the analysis points out the 
presence of Igf1, the insulin-like growth factors. The Igf1 protein, by binding the receptor Igf1R, 
promotes cell proliferation and inhibits apoptosis by blocking the pro-apoptotic protein BAD and by 
phosphorylating apoptosis signal-regulating kinase 1 [37,38]. In relation to this, a study demonstrated 
that blocking the Igf1R and avoiding their binding to the Igf1 protein, an increase in pro-apoptotic 
proteins and a decrease in anti-apoptotic proteins, like Bcl-2 was observed, enhanced the apoptotic 
cascade [39]. 
Notably, Cytoscape/KEGG pathway analysis revealed also exosomal proteins implicated in the 
regulation of actin cytoskeleton, ECM-receptor interaction and focal adhesion. Recent findings 
suggested that cytoskeleton alteration contribute to motoneuron degeneration [40], and that either 
ECM-receptor interaction and focal adhesion are pathways in which are implicated the up-regulated 
genes of ALS patients [41]. In addition, ECM-receptor interaction was identified as reduced in iPSC-
derived motor neurons of patients with C9ALS [42] and has been showed to affect motor neuron in 
ALS model mouse [43]. 
We demonstrated that exosomes induce a neuroprotective effect modulating the apoptotic 
pathway after their internalization by the cells. In particular, we observed a decrease of pro-apoptotic 
proteins, as cleaved-caspase 3 and Bax, and an increase of anti-apoptotic protein Bcl-2 α in cells 
treated with ASC-exosomes. The presence of proteins involved in the PI3K-Akt signaling pathway in 
ASC-exosomes, like Akt, could represent one of the possible mechanism of action by which these 
vesicles exert their effect in an in vitro ALS model. 
Several studies point out that, in ALS patients as well as in the murine models of disease, the 
motoneuron death is due to the activation of the apoptotic pathway [44–49]. In the SOD1(G93A) 
murine model, the inhibition of caspase-1 and caspase-3 have a protective role in ALS, delaying the 
symptom progression and improving survival of animals [44]. Kaspar and colleagues report that the 
delivery of Igf1 in the same murine model prolongs life and delays the ALS progression through the 
PI3K-Akt pathway [47]. These evidences underline that an approach that counteracts the apoptotic 
pathway could be used as a possible therapy in ALS. 
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5. Conclusions 
This study presents a comprehensive proteomic analysis of exosomes derived from murine ASC, 
indicating the possible mechanisms by which ASC-exosomes act. Since these extracellular vesicles 
contain proteins involved in several pathways that stimulate cell survival and proliferation, they 
represent a promising therapeutic approach in different neurodegenerative disease, including ALS. 
Studies conducted with an in vivo model of ALS will be necessary to confirm the possibility of using 
exosomes as therapy. 
Moreover, this study provides the basis to ameliorate the efficacy of this possible non-cell based 
therapy. Indeed, the effect mediated by exosomes could be improved through the use of engineered 
ASC in order to obtain exosomes that contain a higher amount of the molecules responsible for their 
neuroprotective effect. 
Supplementary material: Supplementary Material 1: Table S1. Identified proteins. A total of 189 proteins with a 
peptide confidence cut-off of 99% (FDR < 1%) were identified in ASC-exosomes. Supplementary Material 2: Table 
S2. Transmembrane domains of the identified proteins predicted using the TMHMM program. ExpAA: expected 
number of amino acids in transmembrane helices. Numbers of TDMs: Number or transmembrane domains. 
Supplementary Material 3: Table S3. GO enrichment analysis of the 189 ASC-exosomal proteins using DAVID 
software. GOBPs (A) and GOMFs (B) and GOCCs (C) represented by the ASC-exosomal proteins. The ‘Count’ 
represents the number of proteins with the corresponding GOBPs, GOMFs or GOCCs. The p-values imply the 
significance of being enriched by the exosomal proteins. The percentage represents the portion of the genes 
encoding the proteins with the corresponding GOBPs, GOMFs or GOCCs in the 189 ASC-exosomal proteins. 
Supplementary Material 4: Table S4. KEGG enriched pathways analysis obtained using ClueGO app for 
Cytoscape. ClueGo analysis was performed by setting Bonferroni step down correction (adjusted group p-value 
< 0.05). 
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